

## Antiproliferative prostaglandins activate heat shock transcription factor

CARLA AMICI\*, LEA SISTONEN†, M. GABRIELLA SANTORO‡§, AND RICHARD I. MORIMOTO†

\*Department of Experimental Medicine and Biochemical Sciences, University of Rome Tor Vergata, 00173 Rome, Italy; †Institute of Experimental Medicine, Consiglio Nazionale delle Ricerche, 00156 Rome, Italy; ‡Department of Experimental Medicine, University of L'Aquila, Collemaggio 67100 L'Aquila, Italy; and §Department of Biochemistry, Molecular Biology and Cell Biology, Northwestern University, Evanston, IL 60208

Communicated by E. Margoliash, March 20, 1992

**ABSTRACT** Treatment of human K562 erythroleukemia cells with the antiproliferative prostaglandin A<sub>1</sub> results in the elevated transcription of two heat shock genes, *HSP70* and *HSP90*. Parallel with increased heat shock gene transcription is the activation of heat shock transcription factor. Heat shock transcription factor levels are induced within 60 min after prostaglandin A<sub>1</sub> addition to levels similar to that achieved during heat shock. The requirement for protein synthesis for prostaglandin A<sub>1</sub> activation of heat shock transcription factor suggests that effects on nascent protein synthesis may be involved in the signaling mechanism. Although it is unclear whether the activation of a heat shock response by prostaglandins is relevant to the biochemical properties of these natural substances, cells pretreated with prostaglandin A<sub>1</sub> are protected against a subsequent heat shock, indicative of a thermotolerant state.

Prostaglandins are a class of naturally occurring cyclic 20-carbon fatty acids that are synthesized from polyunsaturated fatty acid precursors in response to external stimuli such as cell injury and inflammation (1). Prostaglandins function as intracellular hormones involved in the regulation of various physiological and pathological processes of eukaryotes, including cell proliferation and differentiation (2), the immune response (3), inflammation (4), cytoprotection (5, 6), and the febrile response (7).

The type A and J prostaglandins, characterized by the presence of a reactive  $\alpha,\beta$ -unsaturated ketone in the cyclopentane ring (cyclopentenone prostaglandins), have antiproliferative activity and cause cultured mammalian cells to arrest in the G<sub>1</sub> phase of the cell cycle (8-10). Human erythroleukemia K562 cells, for example, are extremely sensitive to prostaglandin A<sub>1</sub> (PGA<sub>1</sub>), which results in nearly complete cessation of cell growth at doses that do not affect cell viability and do not suppress DNA or RNA synthesis for at least 24 h (11, 12). Treatment with PGA<sub>1</sub>, PGA<sub>2</sub>, and PGJ<sub>2</sub> results in the elevated synthesis of HSP70, a major heat shock and stress-induced protein (12, 13). Because HSP70 expression is also growth regulated (14, 15), we reasoned that induction of HSP70 by prostaglandins could represent a response to the growth-related effects of this compound. The growth-regulated response of the human *HSP70* gene requires cis-acting elements in the basal promoter that are distinct from the distally located heat shock elements on the heat shock gene promoter, which are necessary for heat shock and other forms of stress responsiveness. The cellular response to a wide range of external stress stimuli, including heat shock, heavy metals, amino acid analogues, oxidizing agents, and teratogens (16), involves the activation of heat shock transcription factor (HSF), which binds to the heat shock element (HSE), comprised of multiple adjacent inverted repeats of the pentamer *nGAA*n (17, 18).

In this study, we show that the cyclopentenone prostaglandin PGA<sub>1</sub> induces in human cells the transcription of classical heat shock genes through activation of HSF. The activation of HSF by PGA<sub>1</sub> requires continued protein synthesis, thus suggesting a role for PGA<sub>1</sub> in the modification of nascent proteins.

### MATERIALS AND METHODS

**Cell Culture.** K562 cells were grown at 37°C in RPMI 1640 medium supplemented with 10% (vol/vol) fetal calf serum at densities of  $1 \times 10^5$  to  $1 \times 10^6$  cells per ml. Prostaglandins (Cayman Chemicals, Ann Arbor, MI), stored as 100% ethanol stock solution (10 mg/ml), were used at a concentration of 4  $\mu$ g/ml, unless differently specified, and control cells received a corresponding volume of ethanol.

**Transcription, mRNA Levels, Protein Synthesis, and Gel Mobility Shift Assays.** *In vitro* run-on transcription reactions were performed in isolated K562 nuclei as described (19). <sup>32</sup>P-labeled RNA was hybridized to nitrocellulose filters containing plasmids for the following human genes, *HSP70* (pH2.3; ref. 20), *HSP90* (pUCHS801; ref. 21), *HSP60* (pUC601; ref. 22), *GRP78/BiP* (pHG23.1; ref. 23), *p72/HSC70* (pHA7.6),  $\beta$ -actin (24), and *c-myc* (pSV-TC; ref. 25), and vector (pGEM2; Promega). Following hybridization, filters were visualized by autoradiography and the radioactivity was quantitated by a Molecular Dynamics Phosphorimager (Molecular Dynamics, Sunnyvale, CA).

Total cytoplasmic RNA was isolated (26), fractionated on 1% agarose/formaldehyde gels, transferred to nitrocellulose, and hybridized with nick-translated <sup>32</sup>P-labeled *HSP70* gene sequences.

Cells were metabolically labeled with [<sup>35</sup>S]methionine for 45 min and equal amounts of protein were analyzed on 10% SDS/PAGE gels. For immunoblot analysis, the nitrocellulose filters were incubated with monoclonal antibody 3A3, which recognizes HSP70 and p72/HSC70 (S. P. Murphy, personal communication). The filters were incubated with horseradish peroxidase-conjugated goat anti-mouse IgG (Boehringer Mannheim), and specific complexes with HSP70 and p72/HSC70 were detected by enhanced chemiluminescence (Amersham).

Whole cell extracts were prepared and binding reactions were performed using a specific heat shock element probe as described (27). HSF-HSE complexes were analyzed by nondenaturing 4% polyacrylamide gel electrophoresis.

### RESULTS

**PGA<sub>1</sub> Induces Transcription of *HSP90* and *HSP70*.** In previous studies it was observed that treatment of cultured human cells with PGA<sub>1</sub>, PGE, and PGF resulted in the elevated synthesis of HSP70 only in cells treated with PGA<sub>1</sub>. To examine whether PGA<sub>1</sub> exerted its effect at the transcriptional level, we measured the effects of PGA<sub>1</sub> on the tran-

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.

Abbreviations: PG, prostaglandin; HSF, heat shock transcription factor; HSE, heat shock element.

scription of a number of human genes, including the heat shock genes *HSP90*, *HSP70*, and *HSP60*, *GRP78/BiP* and *p72/HSC70*, as well as two control (nonstress) genes,  $\beta$ -actin and *c-myc*. Knowledge of which genes were induced by  $\text{PGA}_1$  would reveal whether the effects of  $\text{PGA}_1$  were specific.

To measure the effects of  $\text{PGA}_1$  on transcriptional activation, we performed *in vitro* nuclear run-on assays with nuclei isolated from K562 cells at different times during  $\text{PGA}_1$  treatment. The transcription rate of the *HSP70* gene increased rapidly between 45 and 90 min, attained a maximal 15-fold induction within 3 h, and thereafter declined to basal levels by 10 h (Fig. 1). By comparison, heat shock induced *HSP70* transcription by 50-fold (Fig. 1A, HS). Transcription of *HSP90*, though less striking, exhibited similar kinetics to *HSP70*. In contrast to the relatively rapid induction of *HSP70* and *HSP90*, *GRP78/BiP* transcription was consistently induced 4-fold only at 6 h of  $\text{PGA}_1$  treatment. The transcription of another heat shock gene (*HSP60*), the constitutively expressed *p72/HSC70*, and the control  $\beta$ -actin and *c-myc* genes was unaffected. These results clearly demonstrate that  $\text{PGA}_1$  acts at the transcriptional level and preferentially induces two classical heat shock genes, *HSP70* and *HSP90*.

We examined the effects of  $\text{PGA}_1$  on *HSP70* mRNA levels during  $\text{PGA}_1$  treatment. Cytoplasmic RNA was isolated at different times following  $\text{PGA}_1$  treatment and *HSP70* mRNA levels were measured by Northern blot analysis (Fig. 2A).




FIG. 1. Effects of  $\text{PGA}_1$  treatment on the transcription of control (nonstress) and heat shock genes in K562 cells. (A) Autoradiogram of the relative transcription rates of plasmid vector (pGEM2), *HSP70*, *HSP90*, *HSP60*, *GRP78*, *p72/HSC70*,  $\beta$ -actin, and *c-myc* genes at the indicated times (min, h) during  $\text{PGA}_1$  treatment or following heat shock (at 42°C) for periods of 20, 45, and 90 min. (B) Quantitative analysis using a Molecular Dynamics Phosphorimager analyzer of *HSP70* (●), *HSP90* (▲),  $\beta$ -actin (□), and *c-myc* (○) transcription rates shown in A. The values are expressed as arbitrary units obtained by comparing transcription rates to control levels.





FIG. 2. Effect of  $\text{PGA}_1$  treatment on *HSP70* mRNA levels and *HSP70* protein synthesis and accumulation. (A) Northern blot analysis of cytoplasmic RNA isolated at various times of  $\text{PGA}_1$  treatment on control (C) or heat-shocked (HS) cells. The band at 2.6 kilobases corresponds to the hybridization with the *HSP70* probe and the 1.3-kb band corresponds to the rat glyceraldehyde phosphate dehydrogenase mRNA used as an internal control for the loading of RNA. (B) Autoradiography of SDS/PAGE analysis of [ $^{35}\text{S}$ ]methionine-labeled proteins in control, heat-shocked (HS), or  $\text{PGA}_1$ -treated K562 cells. The positions of *HSP90*, *HSP70*, *GRP78*, and actin are indicated. (C) Western blot analysis of duplicate samples as indicated in B, incubated with the monoclonal antibody 3A3, which recognizes *p72/HSC70* and *HSP70* proteins.

*HSP70* mRNA levels were elevated slightly at 90 min, with maximal *HSP70* mRNA levels detected at 3–6 h. Thus, the increase in *HSP70* mRNA levels followed the increase in *HSP70* transcription rates (compare Fig. 1A to Fig. 2A). The effects of  $\text{PGA}_1$  on the overall levels and patterns of protein synthesis, specifically *HSP70* synthesis, were examined by pulse-labeling with [ $^{35}\text{S}$ ]methionine and SDS/PAGE. Slightly increased levels of *HSP70* synthesis were detected by 90 min of  $\text{PGA}_1$  treatment, coincident with the initial increase in *HSP70* mRNA levels, and reached higher levels of synthesis between 3 and 6 h (Fig. 2B). *HSP90* synthesis was induced slightly after 90 min of  $\text{PGA}_1$  treatment and *GRP78/BiP* synthesis was elevated only at later time points. Synthesis of other stress-responsive proteins and overall levels of protein synthesis were not affected by  $\text{PGA}_1$  treatment. The results of Western blot analysis using a monoclonal antibody (3A3) that recognizes *p72/HSC70* and *HSP70* revealed that *HSP70* levels gradually accumulated during  $\text{PGA}_1$  treatment to a 3-fold higher level by 6–10 h (Fig. 2C). Although the  $\text{PGA}_1$  induction of *HSP70* gene expression was transient, high levels of *HSP70* persisted for periods up to 24 hours. The effects of  $\text{PGA}_1$  appear to be specific to *HSP70* since the levels of *p72/HSC70* were unaltered.

**PGA<sub>1</sub> Treatment Activates HSF.** Two lines of evidence suggested that PGA<sub>1</sub> induced *HSP70* transcription through activation of HSF. First, the kinetics of induction were rapid, and second, two heat shock-induced genes, *HSP70* and *HSP90*, were induced. These results suggest that transcriptional activation is mediated by HSF. To demonstrate whether PGA<sub>1</sub> induced HSF, we used the gel mobility shift assay using a synthetic oligonucleotide containing the consensus HSE binding site from the human *HSP70* promoter. Gel mobility shift assays were performed with whole cell extracts prepared from cells treated with the same dose (4 μg/ml) of PGA<sub>1</sub>, PGE<sub>2</sub>, and PGF<sub>1α</sub>. Only PGA<sub>1</sub> treatment induced the appearance of a HSF–HSE complex, which was indistinguishable from the heat shock-induced HSF–HSE complex (Fig. 3A). HSF–HSE complex formation was detected within 90 min of PGA<sub>1</sub> treatment, attained maximal levels between 3–6 h, and declined after 10 h. Kinetics of HSF DNA-binding activity induced by PGA<sub>1</sub> and heat shock are presented schematically in Fig. 3B, showing a pattern that closely parallels the induction of *HSP70* transcription (Fig. 1A). It was of interest to note that the level of *HSP70* transcription was significantly lower in PGA<sub>1</sub> versus heat-shocked cells even though the levels of HSF were equivalent in cells subjected to either treatment (compare Fig. 1A to Fig. 3A and B). To further characterize the PGA<sub>1</sub>-induced activation of HSF and heat shock gene transcription, we performed a dose–response experiment in which K562 cells were treated for 3 h with different concentrations of PGA<sub>1</sub>. The HSF DNA-binding activity and the *HSP70* transcription were induced when cells were treated with PGA<sub>1</sub> at concentrations >2 μg/ml (data not shown).

**Activation of HSF by PGA<sub>1</sub> Requires Nascent Protein Synthesis.** Little is known about the mechanism of action of the cyclopentenone prostaglandins. It has been reported that PGA<sub>1</sub> is rapidly incorporated into cells and binds to nuclear proteins and DNA (28). One possibility is that PGA<sub>1</sub> interacts with, modifies, and alters the conformation of certain proteins, thus activating the heat shock transcriptional response. To test this hypothesis, we examined whether the PGA<sub>1</sub> induction of heat shock gene transcription and HSF activation was dependent on *de novo* protein synthesis. Cells were treated with 100 μg of cycloheximide per ml for 30 min prior to PGA<sub>1</sub> administration. Cells were removed at various times following treatment and assayed for HSF DNA-binding and transcriptional activities. As shown in Fig. 4A and C, cycloheximide pretreatment abolished the ability of PGA<sub>1</sub> to induce *HSP70* and *HSP90* transcription and activation of HSF. These results strongly suggest that *de novo* protein synthesis is necessary for PGA<sub>1</sub>-induced activation of the heat shock response.

The requirement for protein synthesis for activation of HSF during treatment with PGA<sub>1</sub> contrasts with the requirements for protein synthesis in activation of the heat shock response. Cells were pretreated with cycloheximide and subsequently incubated at 37°C, 42°C, 43°C, and 45°C. As shown in Fig. 4B, *de novo* protein synthesis is required for activation of HSF and heat shock gene transcription at 42°C but not at 43°C and 45°C. These results demonstrate that activation of a 42°C heat shock response is dependent on protein synthesis, which suggests that the mechanism of 42°C heat shock involves damage to nascent translation products. In addition, we suggest that heat shock at 43°C or 45°C affects



**FIG. 3.** Selective induction of HSF DNA-binding activity by PGA<sub>1</sub>. (A) K562 cells were treated with PGA<sub>1</sub>, PGE<sub>2</sub>, and PGF<sub>1α</sub> (formula as shown above each corresponding panel) at 4 μg/ml for indicated time periods, and whole cell extracts were prepared for gel mobility shift assay using the HSE sequence from the human *HSP70* promoter (27). The panel with heat shock (HS) indicates the HSF DNA-binding activity of K562 cells subjected to 42°C for indicated time periods. HSF denotes the induced form of DNA-binding activity, CHBA indicates the constitutive HSE-binding activity (27), and NS denotes nonspecific protein–DNA interactions. (B) The levels of HSF DNA-binding activity in PGA<sub>1</sub>-treated (closed circles) and heat-shocked (open circles) cells were quantitated with a Molecular Dynamics Phosphorimager. HSF values were corrected against the nonspecific (NS) signal and normalized to the level of HSF DNA-binding activity at 45 min of heat shock, which was given a value of 100%.




FIG. 4. Effect of cycloheximide treatment on  $\text{PGA}_1$  activation of HSF and heat shock gene transcription. (A) K562 cells were untreated (–) or treated (+) for 30 min with cycloheximide (100  $\mu\text{g}/\text{ml}$ ) prior to  $\text{PGA}_1$  treatment for periods as indicated. Whole cell extracts were prepared for gel mobility shift assay using the HSE probe. (B) K562 cells were untreated (–) or treated (+) with cycloheximide prior to a 5-min heat shock at 42°C, 43°C, and 45°C. (C) Transcription rates of the *HSP70*, *HSP90*, and  $\beta$ -actin genes measured by nuclear run-on assay from the same samples as shown in A and B (HS at 42°C).

nascent and preexisting proteins, thus providing the signal for activation of the heat shock response that is independent of protein synthesis.

**Exposure to Prostaglandin Attenuates Subsequent Prostaglandin Treatment or Heat Shock Response.** During the continuous exposure of cells to  $\text{PGA}_1$ , the transcriptional induction of *HSP70* and activation of HSF represent a transient response. This can be explained by the depletion of  $\text{PGA}_1$  from the culture medium, reducing the effective concentration, even though  $\text{PGA}_1$  has been shown to be stable over a 24-h period at 37°C (29). An alternative possibility is that cells continuously exposed to  $\text{PGA}_1$  become adapted to  $\text{PGA}_1$ , perhaps related to the transient induction of heat shock gene expression. To distinguish between these possibilities, cells were treated for 15 h with  $\text{PGA}_1$ , during which *HSP70* transcription rates were induced and attenuated, and then treated with an additional aliquot of  $\text{PGA}_1$ . Cells were withdrawn at different time points during the second  $\text{PGA}_1$  treatment and the levels of heat shock gene transcription and HSF DNA-binding activity were measured. Cells that received two treatments of  $\text{PGA}_1$  had a 50% reduction of HSF DNA-binding activity as compared to the levels of HSF achieved in a single  $\text{PGA}_1$  treatment (data not shown). The reduced levels of HSF DNA-binding activity were, however, insufficient to stimulate *HSP70* transcription above basal levels (Fig. 5A). We also examined whether cells treated with  $\text{PGA}_1$  had an altered sensitivity to heat shock.  $\text{PGA}_1$  pretreatment resulted in a consistent 20% reduction in the levels of HSF DNA-binding activity, induced by a 42°C heat shock (data not shown), which corresponded to a 60% reduction in *HSP70* transcription (Fig. 5B). These results exclude the possibility that the transient heat shock response during  $\text{PGA}_1$  treatment is due to depletion of  $\text{PGA}_1$  in the culture medium and suggest that  $\text{PGA}_1$ -treated cells acquire a form of “tolerance” to subsequent exposures to  $\text{PGA}_1$  or heat shock.

## DISCUSSION

The studies presented here demonstrate that  $\text{PGA}_1$  treatment of human K562 cells has a significant effect on the expression of two major heat shock genes, *HSP70* and *HSP90*. The inducible transcription of both genes by  $\text{PGA}_1$  is mediated by HSF, which is activated from its control non-DNA-binding state to a transcriptionally active form. Our studies reveal a surprising specificity of the cyclopentenone prostaglandins since only  $\text{PGA}_1$  induces HSF DNA-binding activity and the closely related PGE and PGF do not induce the heat shock response.

The requirement of protein synthesis for  $\text{PGA}_1$  induction of HSF activation suggests that  $\text{PGA}_1$  may affect nascent pro-

teins at concentrations that inhibit cell proliferation without altering cell viability (12). The effects of  $\text{PGA}_1$  share features common to other inducers of the heat shock response, including heat shock, amino acid analogues, and the nitroourea anti-cancer compounds (27, 30). The requirement for protein synthesis for induction of a heat shock response by these conditions is consistent with the widely held hypothesis that the heat shock response is induced by compounds or conditions that perturb protein synthesis. The coinduction of *GRP78/BiP* in addition to *HSP70* and *HSP90* by  $\text{PGA}_1$ , amino acid analogues, transition heavy metals, and heat shock reveals that  $\text{PGA}_1$ , as for the other conditions, also interferes with nascent protein synthesis in the lumen. Although there is very little information on the *in vivo* consequences of  $\text{PGA}_1$ , there is evidence to support the




FIG. 5. Effect of  $\text{PGA}_1$  pretreatment on the subsequent stress induction of heat shock genes. (A) Kinetics of *HSP70* transcription rates in cells treated with  $\text{PGA}_1$  (4  $\mu\text{g}/\text{ml}$ ) for periods of 0–10 h (open circles) or after a 15-h pretreatment with  $\text{PGA}_1$  (closed circles). (B) Kinetics of *HSP70* transcription rates in cells that were heat shocked for periods of 0–360 min at 42°C (open circles) or heat shocked for the same period after a 15-h pretreatment with  $\text{PGA}_1$  (closed circles).

covalent interaction between  $\text{PGA}_1$  and sulfhydryl groups of cysteine-rich proteins (31, 32). It will be of interest to examine the specificity of  $\text{PGA}_1$  action in greater detail. Is the activation of HSF by  $\text{PGA}_1$  due to direct effects on protein conformation? If  $\text{PGA}_1$  interacts and modifies nascent proteins, it will be important to establish whether there are preferred or specific substrates. Because we have not been able to *in vitro* activate HSF by exogenous  $\text{PGA}_1$  using HeLa cell S100 extracts, it seems unlikely that  $\text{PGA}_1$  acts directly on the control non-DNA-binding form of HSF.

Even though these studies reveal a specific effect of the cyclopentenone prostaglandins on gene expression, an important question is whether the activation of a heat shock-like response by  $\text{PGA}_1$  is biologically relevant to some of the known biological activities of  $\text{PGA}_1$  as antiviral agents (23–29, 33–35) and in the antiproliferative response (10, 13, 36). The effects of prostaglandins and hemin on K562 cells share common features. Hemin treatment causes non-terminal erythroid differentiation, the activation of HSF DNA-binding activity, and the induction of *HSP70*, *HSP90*, and *GRP78/BiP* transcription (ref. 37; L.S. and R.I.M., unpublished data). Prostaglandins and hemin, unlike the traditional inducers of the heat shock response (e.g., inhibitors of energy metabolism, amino acid analogues, antineoplastic compounds), are natural substances. Whether the levels of the cyclopentenone prostaglandins achieve a sufficiently high local concentration *in vivo* to activate HSF and the transcription of the classical heat shock genes in affected cells or tissues has not been examined.

We have found that pretreatment with  $\text{PGA}_1$ , at concentrations that induce HSF DNA-binding activity, diminishes the magnitude of the subsequent stress response. The attenuation of the second exposure to stress, which occurs in  $\text{PGA}_1$ -pretreated cells, may be related to the accumulation of a 2- to 3-fold higher level of HSP70 protein. One explanation is that the induction and accumulation of high levels of HSP70 during the initial exposure to  $\text{PGA}_1$  alters the ability of the treated cell to sense or respond to a subsequent stress stimulus and thus, by direct or indirect means, to regulate the activity of HSF. Consistent with this view, our laboratory has recently shown an interaction between HSP70 and HSF (38).

The role of  $\text{PGA}_1$  in the regulation of the stress response is of particular interest as prostaglandins are a metabolic product of arachidonic acid, a central mediator of the inflammatory response. A possible link between the inflammatory response and the stress response can be suggested from two recent observations. Treatment of HeLa cells with salicylates and indocin, both nonsteroidal antiinflammatory drugs, as well as with arachidonic acid itself induces HSF DNA-binding activity (ref. 39; D. Jurivich, L.S., and R.I.M., unpublished data).

**Note Added in Proof.** Holbrook *et al.* (40) have recently made similar observations on  $\text{PGA}$  effects on the heat shock response.

We thank Sue Fox for excellent technical assistance and Benette Phillips and Klara Abravaya for discussions and advice. These studies were supported by the National Institutes of General Medical Sciences (GM38109), American Cancer Society Faculty Research Award, March of Dimes Foundation, and Progetti Finalizzati "FATMA" and "ACRO" from the Italian National Council of Research. L.S. was supported by a Fogarty International Fellowship from the National Institutes of Health and by a Fellowship from the Academy of Finland.

- Samuelsson, B. (1982) in *Prostaglandins and Cancer: First International Conference*, eds. Powles, T. J., Bochman, R. S., Honn, K. V. & Ramwell, P. (Liss, New York), pp. 1–19.
- Garaci, E., Paolette, R. & Santoro, M. G., eds. (1987) *Prostaglandins in Cancer Research* (Springer, Heidelberg).
- Ninnemann, J. L. (1988) *Prostaglandins, Leukotrienes and the Immune Response* (Cambridge Univ. Press, Cambridge, U.K.).

- Vane, J. R. (1987) in *Prostaglandins in Cancer Research*, eds. Garaci, E., Paolette, R. & Santoro, M. G. (Springer, Heidelberg), pp. 12–28.
- Robert, A. (1981) in *Physiology of the Gastrointestinal Tract*, ed. Johnson, L. R. (Raven, New York), pp. 1407–1434.
- Ruwart, J., Rush, B. D., Friedle, N. M., Piper, R. D. & Kolaja, G. J. (1981) *Prostaglandins* 21, 97–102.
- Dinarello, C. A. & Wolff, S. M. (1982) *Am. J. Med.* 72, 799–819.
- Bhuyan, B. K., Adams, E. G., Badiner, G. J., Li, L. H. & Barden, K. (1986) *Cancer Res.* 46, 1688–1693.
- Hughes-Fulford, M. (1985) *Adv. Prostaglandin Thromboxane Leukotriene Res.* 15, 401–404.
- Santoro, M. G. (1987) in *Prostaglandins in Cancer Research*, eds. Garaci, E., Paolette, R. & Santoro, M. G. (Springer, Heidelberg), pp. 97–114.
- Santoro, M. G., Crisari, A., Benedetto, A. & Amici, C. (1986) *Cancer Res.* 46, 6073–6077.
- Santoro, M. G., Garaci, E. & Amici, C. (1989) *Proc. Natl. Acad. Sci. USA* 86, 8407–8411.
- Ohno, K., Fukushima, M., Fujiwara, M. & Narumiya, S. (1988) *J. Biol. Chem.* 263, 19764–19770.
- Wu, B. J. & Morimoto, R. I. (1985) *Proc. Natl. Acad. Sci. USA* 82, 6070–6074.
- Milarski, K. L. & Morimoto, R. I. (1986) *Proc. Natl. Acad. Sci. USA* 83, 9517–9521.
- Morimoto, R. I., Tissieres, A. & Georgopoulos, C. (1990) *Stress Proteins in Biology and Medicine* (Cold Spring Harbor Lab., Cold Spring Harbor, NY).
- Xiao, H. & Lis, J. T. (1988) *Science* 239, 1139–1142.
- Amin, J., Mestrlil, R., Schiller, P., Dreano, M. & Voellmy, R. (1987) *Mol. Cell. Biol.* 7, 1055–1062.
- Banerji, S. S., Theodorakis, N. G. & Morimoto, R. I. (1984) *Mol. Cell. Biol.* 4, 2437–2448.
- Wu, B., Hunt, C. & Morimoto, R. I. (1985) *Mol. Cell. Biol.* 5, 330–341.
- Hickey, E., Brandon, S. E., Smale, G., Lloyd, D. & Weber, L. A. (1989) *Mol. Cell. Biol.* 9, 2615–2626.
- Hickey, E., Brandon, S. E., Sadis, S., Smale, G. & Weber, L. A. (1986) *Gene* 43, 147–154.
- Watowich, S. S. (1990) Ph.D. thesis (Northwestern University, Evanston, IL).
- Gunning, P., Ponte, P., Okayama, H., Engel, J., Blau, H. & Kedes, L. (1983) *Mol. Cell. Biol.* 3, 787–795.
- Koskinen, P. J., Sistonen, L., Evan, G., Morimoto, R. I. & Alitalo, K. (1991) *J. Virol.* 65, 842–851.
- Theodorakis, N. T. & Morimoto, R. I. (1987) *Mol. Cell. Biol.* 7, 4357–4368.
- Mosser, D. D., Theodorakis, N. G. & Morimoto, R. I. (1988) *Mol. Cell. Biol.* 8, 4736–4744.
- Karmali, R., Schiller, P. & Horrobin, D. F. (1976) *Prostaglandins* 12, 463–469.
- Jaffe, B. M., Behrman, J. & Parker, C. (1973) *J. Clin. Invest.* 52, 398–405.
- Kroes, R. A., Abravaya, K., Seidenfeld, J. & Morimoto, R. I. (1991) *Proc. Natl. Acad. Sci. USA* 88, 4825–4829.
- Ham, E. A., Olien, H. G., Ulm, E. H. & Kuehl, F. A., Jr. (1975) *Prostaglandins* 10, 217–223.
- Khan, S. H. & Sorof, S. (1990) *Proc. Natl. Acad. Sci. USA* 87, 9401–9405.
- Santoro, M. G., Benedetto, A., Carruba, G., Garaci, E. & Jaffe, B. M. (1980) *Science* 209, 1032–1034.
- Santoro, M. G., Garaci, E. & Amici, C. (1991) *Adv. Prostaglandin Thromboxane Leukotriene Res.* 21, 867–874.
- Amici, C. & Santoro, M. G. (1991) *J. Gen. Virol.* 72, 1877–1885.
- Santoro, M. G., Garaci, E. & Amici, C. (1990) in *Stress Proteins: Induction and Function*, eds. Schlesinger, M. J., Santoro, M. G. & Garaci, E. (Springer, Berlin), pp. 27–44.
- Theodorakis, N. G., Zand, D. J., Kotzbauer, P. T., Williams, G. T. & Morimoto, R. I. (1989) *Mol. Cell. Biol.* 9, 3166–3173.
- Abravaya, K., Myers, M. P., Murphy, S. P. & Morimoto, R. I. (1992) *Genes Dev.*, in press.
- Jurivich, D. A., Sistonen, L., Kroes, R. A. & Morimoto, R. I. (1992) *Science* 255, 1243–1245.
- Holbrook, N. J., Carlson, S. G., Choi, A. M. K. & Fargnoli, J. (1992) *Mol. Cell. Biol.* 12, 1528–1534.